Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression

Abstract

OBJECTIVE: Depression is associated with IBD, but the effect of antidepressants on IBD has been sparsely studied. We assessed the impact of depression and antidepressant therapies on the development of IBD. DESIGN: The Health Improvement Network (THIN) was used to identify a cohort of patients with new-onset depression from 1986 to 2012. THIN patients who did not meet the defining criteria for depression were part of the referent group. The outcome was incident Crohn's disease (CD) or ulcerative colitis (UC). Cox proportional hazards modelling was performed to evaluate the rate of Crohn's disease or UC development among patients with an exposure of depression after controlling for age, sex, socioeconomic status, comorbid conditions, smoking, anxiety and antidepressant use including atypical antidepressants, mirtazapine, monoamine oxidase inhibitors (MAOI), serotonin norepinephrine reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI), serotonin modulators; and tricyclic antidepressants (TCA). RESULTS: We identified 403 665 (7.05%) patients with incident depression. Individuals with depression had a significantly greater risk of developing CD (adjusted HR=2.11, 95% CI 1.65 to 2.70) and UC (adjusted HR=2.23, 95% CI 1.92 to 2.60) after controlling for demographic and clinical covariates. SSRI and TCA were protective against CD, whereas mirtazapine, SNRI, SSRI, serotonin modulators and TCA were protective for UC. CONCLUSION: Patients with a history of depression were more likely to be diagnosed with IBD. In contrast, antidepressant treatments were selectively protective for Crohn's disease and UC. These results may impact counselling and management of depression and IBD.

Overview

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2018-317182

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 62 references

Cited by

See all 245

Metadata

Authors
Frolkis, A. D., Vallerand, I. A., Shaheen, A.-A., Lowerison, M. W., Swain, M. G., Barnabe, C., Patten, S. B., & Kaplan, G. G.
Affiliations
University of Calgary (CA)
Corresponding author
Kaplan, Gilaad G
Venue
Gut
Publisher
BMJ
Published
2018-10-18
Volume
68
Issue
9
Pages
1606-1612
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2896255162
Cited by
228
References
62
Citations by year
2026: 15 · 2025: 31 · 2024: 29 · 2023: 35 · 2022: 36 · 2021: 42 · 2020: 21 · 2019: 18 · 2018: 1
FWCI
12.57
Type
journal article
Language
en
Open access
closed
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Institute of Infection and Immunity
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
depression, inflammatory bowel disease, Crohn's disease, ulcerative colitis, antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, mirtazapine, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors
MeSH terms
Adolescent, Adult, Aged, Antidepressive Agents, Colitis, Ulcerative, Crohn Disease, Depression, Female, Follow-Up Studies, United Kingdom, Humans, Male, Middle Aged, Retrospective Studies, Social Class, Inflammatory Bowel Diseases, Comorbidity, Risk Assessment, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. https://app.cochat.ai/papers/10.1136/gutjnl-2018-317182
The paper
Frolkis, A. D., Vallerand, I. A., Shaheen, A.-A., Lowerison, M. W., Swain, M. G., Barnabe, C., Patten, S. B., & Kaplan, G. G. (2019). Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut. https://doi.org/10.1136/gutjnl-2018-317182

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.